MA30314B1 - Traitements contre le cancer - Google Patents

Traitements contre le cancer

Info

Publication number
MA30314B1
MA30314B1 MA31204A MA31204A MA30314B1 MA 30314 B1 MA30314 B1 MA 30314B1 MA 31204 A MA31204 A MA 31204A MA 31204 A MA31204 A MA 31204A MA 30314 B1 MA30314 B1 MA 30314B1
Authority
MA
Morocco
Prior art keywords
against cancer
treatments against
oxaliplatin
liposomes
relates
Prior art date
Application number
MA31204A
Other languages
English (en)
French (fr)
Inventor
Parthenios Boulikas
Original Assignee
Parthenios Boulikas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parthenios Boulikas filed Critical Parthenios Boulikas
Publication of MA30314B1 publication Critical patent/MA30314B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA31204A 2006-03-03 2008-09-02 Traitements contre le cancer MA30314B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20060100144A GR20060100144A (el) 2006-03-03 2006-03-03 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene

Publications (1)

Publication Number Publication Date
MA30314B1 true MA30314B1 (fr) 2009-04-01

Family

ID=38325437

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31204A MA30314B1 (fr) 2006-03-03 2008-09-02 Traitements contre le cancer

Country Status (17)

Country Link
US (1) US20090053302A1 (OSRAM)
EP (1) EP2001441A2 (OSRAM)
JP (1) JP2009528340A (OSRAM)
KR (1) KR20090023548A (OSRAM)
CN (1) CN101522172A (OSRAM)
AU (1) AU2007220263A1 (OSRAM)
BR (1) BRPI0707059A2 (OSRAM)
CA (1) CA2644566A1 (OSRAM)
EA (1) EA200801912A1 (OSRAM)
GR (1) GR20060100144A (OSRAM)
MA (1) MA30314B1 (OSRAM)
MX (1) MX2008011263A (OSRAM)
NO (1) NO20083927L (OSRAM)
RS (1) RS20080388A (OSRAM)
TN (1) TNSN08345A1 (OSRAM)
WO (1) WO2007099377A2 (OSRAM)
ZA (1) ZA200807934B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
KR20080094473A (ko) * 2007-04-20 2008-10-23 한국화학연구원 음이온성 지질나노입자 및 이의 제조방법
EP2236145B1 (en) * 2008-01-28 2014-05-14 NanoCarrier Co., Ltd. Pharmaceutical composition and combined agent
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
EP2259844A4 (en) * 2008-03-05 2012-02-01 Vicus Therapeutics Llc COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGICAL THERAPIES
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
US20120135064A1 (en) * 2009-05-27 2012-05-31 Northeastern University Conjugated nanodelivery vehicles
EP2481396A4 (en) * 2009-09-21 2014-03-05 Jw Pharmaceutical Corp OXALIPLATIN NANOPARTICLES AND MANUFACTURING METHOD THEREFOR
JP5817053B2 (ja) * 2010-04-02 2015-11-18 国立大学法人 千葉大学 腫瘍特異性を有するリポソーム
CN102133176B (zh) * 2011-03-22 2012-09-05 济南宏瑞创博医药科技开发有限公司 一种奥沙利铂胶束制剂及其制备方法及应用
JP5378469B2 (ja) * 2011-08-11 2013-12-25 学校法人 日本歯科大学 医療用薬剤
EP2883542B1 (en) 2012-08-10 2019-05-01 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
MA37931A1 (fr) * 2012-08-13 2016-07-29 Teni Boulikas Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite
US20150258139A1 (en) * 2012-08-13 2015-09-17 Regulon, Inc. Methods for treatment of cancer using lipoplatin
PL2892524T3 (pl) 2012-09-04 2021-10-25 Eleison Pharmaceuticals, Llc Zapobieganie nawrotom płucnym przy użyciu cisplatyny w kompleksie z lipidami
EA023757B1 (ru) * 2012-12-24 2016-07-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы оксалиплатина
CN105451720A (zh) * 2013-03-13 2016-03-30 马林克罗特有限公司 用于癌症疗法的脂质体奥沙利铂组合物
AU2014245147B2 (en) 2013-03-27 2017-08-31 Les Laboratoires Servier Antitumor agent including low-dose irinotecan hydrochloride hydrate
CN103622912B (zh) * 2013-12-05 2016-02-24 常州金远药业制造有限公司 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法
KR20170132152A (ko) * 2015-02-13 2017-12-01 오피 나노 컴퍼니, 리미티드 나노입자를 이용한 종양 치료 조성물 및 방법
JP2018507227A (ja) 2015-03-03 2018-03-15 キュアポート インコーポレイテッド 二薬搭載リポソーム医薬製剤
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
KR101687735B1 (ko) * 2015-09-18 2016-12-19 서울대학교 산학협력단 신규의 동결건조보조제 및 새로운 인지질 용해용 혼합용매를 이용한 리포좀 동결분체의 제조방법
US20190307690A1 (en) * 2016-05-03 2019-10-10 The American University In Cairo Liposomal Delivery Systems for Oxaliplatin and in Dual Drug Delivery in Combination with Chemo-sensitizing and Chemo-therapeutic agents
WO2017192863A1 (en) * 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN106074379B (zh) * 2016-07-11 2019-01-25 中国科学院上海药物研究所 聚乙二醇化奥沙利铂前药及其制备方法和用途
CN112656764B (zh) * 2020-12-28 2022-09-02 吉林大学 一种紫杉醇铂类共载靶向长循环脂质体及应用
CN114814023B (zh) * 2022-04-24 2024-07-30 江苏省中医院 脂质分子在作为胃癌化疗药耐药的预测性标志物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2046997C (en) * 1990-07-16 2000-12-12 Hiroshi Kikuchi Liposomal products
US6060080A (en) * 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
CN1254234C (zh) * 2000-06-09 2006-05-03 莱古伦公司 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
JP3415131B1 (ja) * 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
CN1681478A (zh) * 2002-08-02 2005-10-12 川塞夫有限公司 铂聚集体及其制备方法
US20070160656A1 (en) * 2003-05-02 2007-07-12 Dziewiszek Krzysztof J Lipid platinum complexes and methods of use thereof
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents

Also Published As

Publication number Publication date
GR20060100144A (el) 2007-10-17
KR20090023548A (ko) 2009-03-05
WO2007099377A2 (en) 2007-09-07
CA2644566A1 (en) 2007-09-07
NO20083927L (no) 2008-09-15
ZA200807934B (en) 2009-11-25
MX2008011263A (es) 2008-12-12
CN101522172A (zh) 2009-09-02
RS20080388A (sr) 2009-07-15
EA200801912A1 (ru) 2009-02-27
WO2007099377A3 (en) 2008-04-17
EP2001441A2 (en) 2008-12-17
US20090053302A1 (en) 2009-02-26
JP2009528340A (ja) 2009-08-06
BRPI0707059A2 (pt) 2011-04-19
TNSN08345A1 (en) 2009-12-29
AU2007220263A1 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
EA200801912A1 (ru) Лечение рака
WO2006099169A3 (en) Novel liposome compositions
AU307299S (en) Gaming assembly
WO2008030818A3 (en) Novel liposome compositions
IL173052A0 (en) Lipid encapsulated interfering rna
IL173478A0 (en) Form of administration secured against misuse
WO2008063808A3 (en) Encapsulated peptide amphiphile nanostructures
EP1758595A4 (en) Use of lipid conjugates in the treatment of diseases
EP1635764A4 (en) CONJUGATE FOR THE SPECIFIC TARGETING OF ANTICANCER AGENTS ON CANCER CELLS AND PRODUCTION OF THE CONJUGATE
WO2007016352A3 (en) Oral liquid losartan compositions
WO2004098524A3 (en) Lipid platinum complexes and methods of use thereof
IL174305A0 (en) 5-arylpyrimidines as anticancer agents
EP1796729A4 (en) LIPOSOME WITH IMPROVED ARZNE RETENTION FOR THE TREATMENT OF CANCER
WO2007067784A3 (en) Liposomal compositions
PL1715851T3 (pl) Dostosowane dla konsumenta postacie dawki
EP1795182A4 (en) LIPOSOME IMPROVING INTRACELLULAR DRUG DELIVERY
GB0413587D0 (en) Well treatment
NO20063418L (no) Konsumenttilpassede dosringsformer
WO2007140804A8 (en) A process for the preparation of an oxaliplatin
GB2430408B (en) Decorative inlays
HK1101057A (en) Improved anticancer treatment
AU2004904700A0 (en) Improved anticancer treatment
ZA200710722B (en) Variants at Chr8q24.21 confer risk of cancer
AU2003271237A1 (en) Therapeutic brassiere
HK1085947A (en) 5-arylpyrimidines as anticancer agents